Ceop-21 Versus Ceop-14 Chemotherapy With or Without Rituximab for the First-line Treatment of Patients With Aggressive Lymphomas: Results of the He22a99 Trial of the Hellenic Cooperative Oncology Group

Abstract:Background:In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lympho